S-P settles Clarinex suit
This article was originally published in The Tan Sheet
Schering-Plough agrees to pay $165 million to settle a class-action lawsuit that news reports indicate is related to the firm's alleged failure to disclose information about the FDA review of the prescription allergy product. In a Feb. 27 posting on its Web site, Schering says the settlement was preliminarily approved by a federal court in Newark, N.J., and a final approval hearing is slated for June 1. The firm's online statement does not identify the subject of the settlement, but states the amount. Investors involved in the litigation said the company failed to disclose manufacturing problems that blocked the approval of Clarinex and led to a 2002 FDA consent decree against Schering (1"The Tan Sheet" Jan. 10, 2005, p. 5). Clarinex (desloratadine) has been mentioned as a potential OTC switch candidate (2"The Tan Sheet" Feb. 5, 2007, p. 4)
You may also be interested in...
The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29
The impact of Schering-Plough's 2002 consent decree has produced the side benefit of transforming the firm into an industry model for good manufacturing practices, according to CEO Fred Hassan
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.